Biohaven Pharmaceutical Holding (BHVN) PT Raised to $165 at Cowen
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/28/2026
- Wall St slips as oil spikes after Trump rejects Iran peace proposal
- S&P 500 breadth hits lowest level since dot-com bubble, Goldman says
- Nvidia’s AI dominance funds historic $150 billion buyback
- MongoDB stock drops 15% as CEO Desai resigns for Meta
- Jefferies cuts Roblox to Underperform, says rally is too optimistic
- Oppenheimer sees AI software winners as focus shifts to ROI
- Exclusive-Activist Jana pushes Fiserv to accelerate cost cuts and tap Palantir
- Cantor Fitzgerald Starts Lexicon Pharmaceuticals (LXRX) at Overweight
- S&P 500 breadth hits lowest level since dot-com bubble, Goldman says
- Bloom Energy shares fall on Oracle project halt
Biohaven Pharmaceutical Holding (BHVN) PT Raised to $160 at H.C. Wainwright
October 6, 2021 6:39 AM EDTH.C. Wainwright analyst Douglas Tsao raised the price target on Biohaven Pharmaceutical Holding (NYSE: BHVN) to $160.00 (from $135.00) while maintaining a Buy rating.
The analyst commented, "Nurtec once again exceeded expectations, demonstrating the strong commercial execution as well as the drugs unique profile both treating and preventing migraines. Preliminary sales clocked in at $136M, up 46% Q/Q; about 33% above our estimates at $102M and roughly 20% above consensus at... More
